On Monday, Avenue Therapeutics Inc (NASDAQ: ATXI) opened lower -7.75% from the last session, before settling in for the closing price of $0.14. Price fluctuations for ATXI have ranged from $0.11 to $1.28 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 58.16% at the time writing. With a float of $39.43 million, this company’s outstanding shares have now reached $44.26 million.
The firm has a total of 3 workers. Let’s measure their productivity.
Avenue Therapeutics Inc (ATXI) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Avenue Therapeutics Inc is 10.92%, while institutional ownership is 2.79%. The most recent insider transaction that took place on Dec 11 ’23, was worth 49,600. In this transaction 10% Owner of this company sold 353,000 shares at a rate of $0.14, taking the stock ownership to the 22,000 shares. Before that another transaction happened on Dec 11 ’23, when Company’s 10% Owner sold 264,000 for $0.14, making the entire transaction worth $36,960. This insider now owns 681,000 shares in total.
Avenue Therapeutics Inc (ATXI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 51.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.16% per share during the next fiscal year.
Avenue Therapeutics Inc (NASDAQ: ATXI) Trading Performance Indicators
Check out the current performance indicators for Avenue Therapeutics Inc (ATXI). In the past quarter, the stock posted a quick ratio of 1.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Avenue Therapeutics Inc (ATXI)
Analysing the last 5-days average volume posted by the [Avenue Therapeutics Inc, ATXI], we can find that recorded value of 0.99 million was lower than the volume posted last year of 4.76 million. As of the previous 9 days, the stock’s Stochastic %D was 17.09%. Additionally, its Average True Range was 0.01.
During the past 100 days, Avenue Therapeutics Inc’s (ATXI) raw stochastic average was set at 5.20%, which indicates a significant decrease from 22.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.43% in the past 14 days, which was lower than the 167.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1512, while its 200-day Moving Average is $0.4629. Now, the first resistance to watch is $0.1383. This is followed by the second major resistance level at $0.1515. The third major resistance level sits at $0.1631. If the price goes on to break the first support level at $0.1135, it is likely to go to the next support level at $0.1019. Should the price break the second support level, the third support level stands at $0.0887.
Avenue Therapeutics Inc (NASDAQ: ATXI) Key Stats
There are currently 44,261K shares outstanding in the company with a market cap of 5.53 million. Presently, the company’s annual sales total 0 K according to its annual income of -10,380 K. Last quarter, the company’s sales amounted to 0 K and its income totaled 640 K.
